加载中
NASDAQHealthcareBiotechnology
最新数据
US$0.5474
−US$0.0181 · -3.20%
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
常规交易时段
US$0.5474
−US$0.0181 · -3.20%
盘中时间采用ET。市场数据可能有所延迟。
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
日内区间
当前US$0.5474
52周区间
当前US$0.5474
盘中时间采用ET。市场数据可能有所延迟。
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
日内区间
当前US$0.5474
52周区间
当前US$0.5474
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 843.6万 USD | 846.8万 USD | 868.7万 USD | 871.3万 USD | 402.5万 USD |
| 毛利 | −843.6万 USD | −846.8万 USD | −868.7万 USD | −871.3万 USD | −402.5万 USD |
| 研究与开发 | 6860.7万 USD | 8674.2万 USD | 9803.8万 USD | 9453.7万 USD | 5439.3万 USD |
| 销售、一般及管理费用 | 2472.4万 USD | 2073.8万 USD | 2446.8万 USD | 2237.1万 USD | 1438.8万 USD |
| 营业费用 | 8489.5万 USD | 1.07亿 USD | 1.23亿 USD | 1.17亿 USD | 6878.1万 USD |
| 利息收入 | 268.2万 USD | 473.7万 USD | 705.6万 USD | 195.4万 USD | 10.8万 USD |
| 折旧和摊销 | 843.6万 USD | 846.8万 USD | 868.7万 USD | 646.7万 USD | 296.1万 USD |
| 营业利润 | −9333.1万 USD | −1.16亿 USD | −1.31亿 USD | −1.26亿 USD | −7280.6万 USD |
| 净利润 | −9059.7万 USD | −1.11亿 USD | −1.24亿 USD | −1.24亿 USD | −7272.1万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$2.33
上涨空间 325.65%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI353.27万0.00%2.3万亿 USD0.03%US$381.06-0.13%
Vanguard Extended Market ETFVXF121.64万0.00%954亿 USD0.05%US$232.46-0.46%
iShares Biotechnology ETFIBB93.02万0.01%108.2亿 USD0.44%US$202.03-1.09%
Invesco RAFI US 1500 Small-Mid ETFPRFZ17.24万0.01%26.7亿 USD0.36%US$52.79-0.25%
Invesco NASDAQ Future Gen 200 ETFQQQS10.12万0.44%2275.83万 USD0.20%US$40.97-1.07%
Invesco Nasdaq Biotechnology ETFIBBQ9226.770.01%1.12亿 USD0.19%US$33.865-1.12%
ProShares Ultra Nasdaq BiotechnologyBIB4871.220.01%9138.97万 USD1.19%US$106.33-2.27%
Avantis Total Equity Markets ETF 1AVTM2131.44—7.93亿 USD0.23%US$55.51-0.00%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBInvesco RAFI US 1500 Small-Mid ETFPRFZInvesco NASDAQ Future Gen 200 ETFQQQSInvesco Nasdaq Biotechnology ETFIBBQProShares Ultra Nasdaq BiotechnologyBIBAvantis Total Equity Markets ETF 1AVTMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
